Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma In Situ of the Bladder
Roger Li, Wade J. Sexton, Jasreman Dhillon, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 19, pp. 3875-3881
Closed Access | Times Cited: 13

Showing 13 citing articles:

Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
Roger Li, Paras Shah, Tyler F. Stewart, et al.
Nature Medicine (2024) Vol. 30, Iss. 8, pp. 2216-2223
Closed Access | Times Cited: 19
Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Roger Li, Patrick J. Hensley, Shilpa Gupta, et al.
European Urology (2024) Vol. 86, Iss. 6, pp. 516-527
Closed Access | Times Cited: 9
Molecular biomarkers of progression in non-muscle-invasive bladder cancer — beyond conventional risk stratification
Mitchell Olislagers, Florus C. de Jong, Vera C Rutten, et al.
Nature Reviews Urology (2024)
Closed Access | Times Cited: 4
From Bench to Bladder: The Rise in Immune Checkpoint Inhibition in the Treatment of Non-Muscle Invasive Bladder Cancer
Cara C. Burns, Jacob M. Parker, Dylan M. Schaap, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1135-1135
Open Access
Optimizing outcomes for high-risk, non-muscle-invasive bladder cancer: The evolving role of PD-(L)1 inhibition
Jens Bedke, Peter C. Black, Bernadett Szabados, et al.
Urologic Oncology Seminars and Original Investigations (2023) Vol. 41, Iss. 12, pp. 461-475
Open Access | Times Cited: 9
An evaluation of durvalumab across the spectrum of urothelial carcinoma
Ek Leone Oh, Andrew Redfern, Dickon Hayne
Expert Review of Anticancer Therapy (2024)
Closed Access | Times Cited: 2
Treatment Strategies for BCG Unresponsive Non-muscle Invasive Bladder Cancer
Anusha Gupta, Shiv Verma, Sanjay Gupta
annals of urologic oncology (2024)
Open Access
Bacillus Calmette-Guérin (BCG) Refractory Non-Muscle-Invasive Bladder Cancer (NMIBC): Current Guidance and Experience from Clinical Practice
Angelo Naselli, Giacomo Maria Pirola, Daniele Castellani
Research and Reports in Urology (2024) Vol. Volume 16, pp. 299-305
Open Access
Unmet Need in Non–muscle-invasive Bladder Cancer Failing Bacillus Calmette-Guérin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group
David D’Andrea, Hugh Mostafid, Paolo Gontero, et al.
European Urology Oncology (2024)
Open Access
Bioinspired micro‐ and nanostructured systems for cancer therapy
Ruizhen Yang, Bing Zhang, Xiawei Fei, et al.
MedComm (2024) Vol. 5, Iss. 12
Closed Access
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Yuhao Shi, Amber McKenery, Melissa Dolan, et al.
EMBO Reports (2024)
Open Access
State of the art of adjuvant immunotherapy in urothelial cancer: New developments and upcoming changes
Elisa Tassinari, Linda Danielli, Andrea Marchetti, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 21, Iss. 1
Open Access
The Emerging Landscape of Mouse Bladder Cancer Models
Tomoko Iwata, Amal Rahil Elgaddafi Yousef
(2024), pp. 317-341
Closed Access
Page 1

Scroll to top